Intuitive Surgical initiated with an Outperform, $377 target at Baird

As previously reported, Baird initiated coverage of Intuitive Surgical with an Outperform rating and $377 price target. As the “pioneer” in soft tissue robotic assisted surgery, Intuitive should continue to deliver a mid-teens compound annual growth rates in revenue and EPS as the worldwide daVinci installed base expands and ongoing conversions to robotic assisted surgery continue, the analyst tells investors in a research note.